TABLE 2.
Apoptosis-related lncRNAs in brain tumors.
| Genomic coordinates | Brain tumors | lncRNA | Targets | Model | Type of cell line | Ref | |
|---|---|---|---|---|---|---|---|
| Up regulated lncRNAs expression | p36.32 chr1:3735510–3745905 (-) | Medulloblastoma | TP73-AS1 | miR-494-3p/EIF5A2 | In vivo | specimens of medulloblastoma human medulloblastoma cell lines Daoy, D341 animal experiment | Li et al. (2019b) |
| E-cadherin, N-cadherin, Vimentin | In vitro | ||||||
| p36.32 chr1:3735510–3745905 (-) | Medulloblastoma | TP73-AS1 | Capase-3 | In vivo | cell lines UW228.2, MED8A and ONS76, DAOY/mice | Varon et al. (2019) | |
| In vitro | |||||||
| p35.3 chr1:28505979–28510892 (+) | Glioblastoma | SNHG3 | Human, in vitro | glioma tissue/cell lines (A172, U251, U87, and SHG44) | Fei et al. (2018) | ||
| p35.3 chr1:28578537–28581010 (-) | Glioblastoma | SNHG12 | HuR | In vitro | tumor samples U87, LN229, U373, U251 | Lei et al. (2018) | |
| q27.3 chr3:188151205–188154057 (-) | Glioblastoma | LPP-AS2 | miR-7-5p/EGFR/PI3K/AKT/and c-MYC PI3K/AKT pathway | In vitro | Glioma tissues U251, U87, SHG44, T98G, GOS-3, TJ905, U373 | Zhang et al. (2020a) | |
| In vivo | |||||||
| q26.33 chr3:180989761–181117494 (+) | Glioblastoma | SOX2-OT | MiR-194-5p, miR-122 | In vivo | U87 and U251 cell lines | Su et al. (2017) | |
| q13.2 chr4:67701208–67723914 (+) | Glioblastoma | UBA6-AS1 | miR-760/HOXA2 | In vivo | GBM tissues/GBM cell lines A172 and U251 | Cheng et al. (2021) | |
| In vitro | |||||||
| q25 chr4:108167524–108176426 (+) | Glioblastoma | LEF1-AS1 | ERK1/2 and Akt/mTOR pathway | In vivo | GBM tissues Human U251 and U87 glioma cells | Wang et al. (2017) | |
| Bax and Bcl-2 | In vitro | ||||||
| q14.1 chr5:78360610–78476026 (+) | Glioblastoma | SCAMP1 | Wnt/β‐catenin | In vivo | Glioma specimens U87, U251, HEK293T mice | Zong et al. (2019) | |
| p15.2 chr7:27184506–27189298 (+) | Glioblastoma | HOXA11-AS | miR-130a-5p/HMGB2 | In vitro | Glioma tissues and U251 and U87MG cells | Xu et al. (2019b) | |
| In vivo | |||||||
| p11.2 chr7:55179749–55188934 (-) | Glioblastoma | EGFR-AS1 | miR-133b/RACK1 | In vitro | Human U87, U251 and T Human glioma specimens98 G | Dong et al. (2019) | |
| N-cadherin, Vimentin and MMP-2, Bax, cleaved Caspase-3 and PARP | In vivo | ||||||
| q34 chr7:141704002–141738230 (-) | Glioblastoma | WEE2-AS1 | miR-520f-3p/SP1 | In vivo | GBM tissues/GBM cell lines T98 and U138/mice | Lin et al. (2021) | |
| In vitro | |||||||
| p15.2 chr7:27095646–27096327 (+) | Glioblastoma | HOTAIRM1 | HOXA1 | In vivo | U87, U251, and A172 cell lines glioma tissues | Li et al. (2018) | |
| In vitro | |||||||
| p15.2 chr7:27095646–27096327 (+) | Glioblastoma | HOTAIRM1 | miR-873-5p/ZEB2 | In vitro | U87, LN-229, U-251, and A172 | Lin et al. (2020) | |
| Cyclin A1, Cyclin D1, Bcl-2, Caspase-3 | |||||||
| q13.1 chr8:66921683–66925541 (-) | Glioblastoma | SNHG6 | miR-876-5p/ERLIN2 axis | In vitro | LN-215, ADF, U138, A-382 | Du and Hou, (2020) | |
| q24.21 chr8:127794525–128101256 (+) | Glioblastoma | PVT1 | Bax/bcl2/caspase 3 | In vivo | glioma cell lines U87MG and U251/glioma tissue/mice | Yang et al. (2017) | |
| In vitro | |||||||
| p11.22 chr10:31206277–31319691 (-) | Glioblastoma | ZEB1-AS1 | Bax/bcl2 | In vivo in vitro | HS683, T98G, U87, U251 glioma tissues | Lv et al. (2016) | |
| p15.1 chr10:4201140–4243912 (-) | Meningioma | LINC00702 | miR-876-5p/ERLIN2 axis | In vitro | LN-215, ADF, U138, A-382 | Du and Hou, (2020) | |
| q13.1 chr11:65497687–65506431 (+) | Glioblastoma | MALAT1 | miR-199a/ZHX1 | In vivo | Glioma tissues | Liao et al. (2019a) | |
| Bcl-2/Bax | In vitro | U87-MG, U251, T98G, and A172 | |||||
| q13.1 chr11:65422773–65426457 (+) | Glioblastoma | NEAT1 | miRNA let-7e/NRAS | Human, In vitro | glioma tissues | Gong et al. (2016) | |
| U87, T98G, U251, A272 and U373 cell lines | |||||||
| p15.5 chr11:1995175–1996191 (-) | Glioblastoma | H19 | Notch signaling pathway | In vivo | GBM tissue GBM cell lines (M059K, LN-229, T98G, and U343) mice | Wu et al. (2021) | |
| In vitro | |||||||
| p15.5 chr11:2608327–2699994 (-) | Glioblastoma | KCNQ1OT1 | miR-370/CCNE2 | In vitro | cell lines (U87, U251)/glioma tissues/mice | Gong et al. (2017) | |
| In vivo | |||||||
| q24.23 chr12:120201290–120213231 (+) | Glioblastoma | PXN-AS1 | Wnt/β-catenin pathway | In vivo | A172, U251, U87, LN229 | Chen et al. (2020) | |
| Animal sample | |||||||
| q13.13 chr12:53962307–53974956 (-) | Medulloblastoma | HOTAIR | miR-1/miR-206/YY1 | In vivo | primary medulloblastoma samples | Zhang et al. (2020c) | |
| Human cells, Daoy, D283 med and D34 | |||||||
| q13.13 chr12:53962307–53974956 (-) | Medulloblastoma | HOTAIR | caspase-3,9/bcl2/bax | In vivo | medulloblastoma cell lines Daoy and D341/mice | Zhao et al. (2020) | |
| q13.13 chr12:53962307–53974956 (-) | Glioblastoma | HOTAIR | Caspase-3 | In vivo | U-87 and A172 cell lines/GBM samples/mice | Zhang et al. (2020b) | |
| In vitro | |||||||
| q14.1 chr12:57726270–57728356 (+) | Glioblastoma | AGAP2-AS1 | TFPI2 | In vivo | GBM tumor tissues | Luo et al., 2019) | |
| In vitro | GBM cell lines (A172, U87/MG, U251/MG, LN229, and SHG44) | ||||||
| q14.2 chr13:50082168–50107202 (+) | Glioblastoma | DLEU1 | miR-4429 | ? | U251, U87 and LN229 | Liu et al. (2019) | |
| Bcl-2/Bax/caspase-3 | |||||||
| q24.1 chr15:73908070–73919870 (-) | Medulloblastoma | LOXL1-AS1 | PI3K-AKT | In vivo | Human tissues | Gao et al. (2018) | |
| In vitro | Human medulloblastoma cell lines cell lines Daoy, D283, D425, D341, and D458 | ||||||
| q12.2 chr16:54845188–54848278 (-) | Medulloblastoma | CRNDE | miR-101-3p | In vivo | glioma tissues U87, U251, LN229, T98G Mice | Meng et al. (2018) | |
| q24.3 chr17:72030290–72036316 (+) | Glioblastoma | LINC01152 | caspase-3 | In vivo | cell lines D283, Daoy, D425, D341, and D458/Human Samples/Mouse | Song et al. (2016) | |
| In vitro | |||||||
| q25.1 chr17:76557763–76564689 (+) | Glioblastoma | SNHG16 | Bcl/bax/caspase-3/PI3K/Akt | In vitro | brain glioma specimens/U251, H4, SW1783 and LN229 cells/ | Lu et al. (2018) | |
| q25.2 chr17:77086715–77093762 (+) | Glioblastoma | SNHG20 | PI3K/Akt/mTOR | in vivo | glioblastoma tissues glioblastoma cell lines (U87MG, U343, U251, LN215) | Gao et al. (2019b) | |
| p11.31 chr18:3466249–3473203 (+) | Glioblastoma | GAPLINC | miR-331-3p | in vitro | GBM cell lines (T98G, U251, LN18, LN229, and A172) | Chen et al. (2019) | |
| in vivo | |||||||
| q11.2 chr18:22164885–22167781 (-) | Glioblastoma | GATA6-AS1 | TUG1 | In vitro | Tumor tissues glioma cell lines Hs 683 and CCD-25Lu | Liao et al. (2019b) | |
| q11.23 chr20:38419637–38435375 (-) | Astrocytoma | SNHG17 | Caspase 3/bcl2/bax | In vitro | cell lines U87MG, U251, U343, Hs683, LN215 and A172 | Li et al. (2016) | |
| q21.3 chr21:25582769–25583326 (-) | Glioblastoma | LINC00515 | miR-16/PRMT5 | In vivo | Glioma tissue/Human glioma cell lines U251, U87MG, LN229 | Wu and Lin, (2019) | |
| q22.3 chr21:4,3461959–43478223 (-) | Glioblastoma | Linc-00313 | UPF1-Linc-00313-miR-342-3p/miR-485-5p-Zic4-SHCBP1 | In vivo | (GBM) cell lines U87, U251/glioma tissues/mice | Shao et al. (2019) | |
| q13.31 chr22:47630827–48023030 (+) | Globlastoma | EPIC1 (LOC284930) | Notch signaling pathway | In vivo | GBM tissue GBM cell lines (M059K, LN-229, T98G, and U343) mice | Wu et al. (2021) | |
| In vitro | |||||||
| Down regulated lncRNAs expression | p35.2 chr1:30718503–30726744 (+) | Glioblastoma | MATN1-AS1 | RELA | in vivo in vitro | U87MG and U251 | Han et al. (2019) |
| ERK1/2, Bcl-2, survivin, andMMP-9, Bax | GBM tissue | ||||||
| p35.2 chr1:30718503–30726744 (+) | Glioblastoma | MATN1-AS1 | Bcl/bax | In vivo | GBM cells U87MG and U251/GBM tissue specimens/mice | Han et al. (2019) | |
| In vitro | |||||||
| q25.1 chr1:173858558–173867045 (-) | Glioblastoma | GAS5 | Bcl-2\bax | In vivo | cell lines (U87 and U251)/glioma tissues/mice | Zhao et al. (2015) | |
| In vitro | |||||||
| q12.1 chr5:60487712–60491518 (+) | Glioblastoma | PART1 | PI3K/AKT | In vitro, human | U87MG, LN-18, LN-428 glioma tissues | Jin et al. (2020a) | |
| Bcl2/bax | |||||||
| p15.2 chr7:27198574–27201236 (+) | Glioblastoma | HOTTIP | P53 | In vivo in vitro | A172, U251, U87-MG, U118-MG glioma tissues mice | Xu et al. (2016) | |
| q21.3 chr7:94022832–94064723 (+) | Glioblastoma | AC003092.1 | miR-195/TFPI-2 signaling | In vivo | Human U87 cell line/glioma tissues/mice | Xu et al. (2018a) | |
| In vitro | |||||||
| p13.3 chr9:33775182–33801186 (-) | Glioblastoma | UBE2R2-AS1 | miR-877-3p/TLR4 | In vitro | U251, A-172, U87-MG, and U373 glioma samples | Xu et al. (2019c) | |
| caspase-3/-7/-8 and Bcl2 | In silico | ||||||
| q26.11 chr10:118046278–118206659 (+) | Glioblastoma | CASC2 | miRNA-18a | In vitro | glioblatoma tissue | Wang et al. (2020b) | |
| E-cadherin | In vivo | Human glioblastoma cells (A172 and T98) | |||||
| p14.1 chr11:27506829–27515218 (+) | Glioblastoma | BDNF-AS | PABPC1-BDNF- AS-RAX2-DLG5 pathway | In vivo | U87 and U251 Glioma tissues Mice | Su et al. (2020) | |
| q13.1 chr11:65422773–65426457 (+) | Glioblastoma | NEAT1 | miR-92b/DKK3 pathway | U-87 MG and U251 glioma tissues | Liu et al. (2020) | ||
| q13.12 chr19:36259539–36264788 (-) | Glioblastoma | LINC00665 | TAF15/LINC00665/MTF1(YY2)/GTSE1 axis | In vivo | U251 and U87 glioma cells/glioma tissues/mice | Ruan et al. (2020) | |
| In vitro | |||||||
| q11.23 chr20:36045617–36051018 (-) | Glioblastoma | LINC00657 (NORAD) | miR-190a-3p/PTEN | In vivo | U-87 MG, LN-18 and U-118 MG | Chu et al. (2019) | |
| PI3K/Akt/mTOR | In vitro | Animal cases |